The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 350.00
Bid: 350.00
Ask: 355.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.429%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 350.00
APTD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

6 Jul 2017 07:00

RNS Number : 2365K
Microgen PLC
06 July 2017
 

6 July 2017

 

MICROGEN plc ('Microgen' or 'Group')

 

TRADING UPDATE AND NOTICE OF RESULTS

 

 

Ahead of announcing Interim Results for the six months ended 30 June 2017 on 24 July 2017, Microgen (MCGN.L), a leading provider of business critical software and services, today issues the following update on trading for the financial year to date.

The Group has made excellent progress in the first half of 2017 resulting in a financial performance ahead of the Board's original expectations for the period whilst maintaining margins consistent with the prior year. The Group's two businesses are successfully executing their declared strategy with Aptitude Software delivering strong organic growth and Microgen Financial Systems successfully continuing on its transition towards a business focused on the Trust & Fund Administration ('T&FA') market.

A key highlight for the Group is the continued new business wins that have driven growth in Aptitude Software's recurring revenue base. Since 30 June 2016, the recurring revenue in Aptitude Software has increased 42% to £15.0 million as at 30 June 2017 (H1, 2016: £10.6 million and 31 December 2016: £12.6 million). There has also been exceptional growth in demand for Aptitude Software's implementation services in the first half of the year as a number of clients progress towards going live with the Aptitude Revenue Recognition Engine ('ARRE'). Upon completion of the half year the Board has reviewed the on-going demand for Aptitude Software's implementation services and, whilst clients' requirements continue to evolve, the Board is now confident that the exceptional level of demand experienced in the first six months of the year will continue throughout 2017, leading to a financial performance for the Group significantly ahead of the Board's expectations for the year. 

Opportunities for Aptitude's existing software and its new products provide the business with confidence for future years. Partners are becoming an increasingly important channel for new business, and as they provide a growing proportion of resources for new implementations, and as a number of the larger ARRE projects are completed, the exceptional level of demand for services experienced in 2017 is expected to moderate in 2018.

Microgen Financial Systems has maintained its focus on the T&FA market within the wealth management sector. The acquisition of Primacy Corporation in February 2017, a competitor in the T&FA market, represented the fifth acquisition since December 2014 and further strengthens the position of the business in this market. As a result of this focus T&FA revenues now represent approximately 60% of Microgen Financial Systems' H1 2017 revenue (H1, 2016: 51%), compared to 33% at the beginning of this transition in 2014.

 

Contacts

Ivan Martin, Chairman 020-7496-8100

Philip Wood, Chief Financial Officer

 

James Melville-Ross / Darius Alexander 020-3727-1000

FTI Consulting

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUUGMUPMGAA
Date   Source Headline
28th Jul 202312:18 pmRNSHolding(s) in Company
28th Jul 20237:00 amRNSHolding(s) in Company
27th Jul 20231:52 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSInterim Results
24th Jul 20235:22 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSHolding(s) in Company
19th Jul 20237:00 amRNSDirector Retirement
13th Jul 20237:00 amRNSTrading Update and Directorate Changes
23rd Jun 20234:43 pmRNSHolding(s) in Company
16th Jun 20234:22 pmRNSHolding(s) in Company
25th May 20235:22 pmRNSDirector/PDMR Shareholding
24th May 202311:01 amRNSHolding(s) in Company
23rd May 20236:10 pmRNSDirector/PDMR Shareholding
23rd May 20233:27 pmRNSHolding(s) in Company
17th May 202311:24 amRNSResult of AGM
17th May 20237:00 amRNSAGM Statement and Appointment of CFO
2nd May 202311:44 amRNSHolding(s) in Company
24th Apr 20235:13 pmRNSExercise of awards under 2020 Deferred Bonus Plan
20th Apr 202311:30 amRNSGrant of awards under 2020 Deferred Bonus Plan
17th Apr 202311:49 amRNSHolding(s) in Company
17th Apr 20238:32 amRNSHolding(s) in Company
29th Mar 20234:36 pmRNSDirector/PDMR Shareholding
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202311:27 amRNSBLOCK LISTING SIX MONTHLY RETURN
21st Mar 20237:00 amRNSAudited Results for Year Ended 31 December 2022
13th Feb 20235:20 pmRNSHolding(s) in Company
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSHolding(s) in Company
24th Jan 20237:00 amRNSFull Year Trading Update and Directorate Change
12th Jan 20239:51 amRNSNew Directorship Notification
24th Nov 20227:00 amRNSGrant of awards under Performance Share Plan
8th Nov 20227:00 amRNSGrant of awards
21st Oct 20224:41 pmRNSSecond Price Monitoring Extn
21st Oct 20224:36 pmRNSPrice Monitoring Extension
28th Sep 20227:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
28th Jul 20227:00 amRNSInterim Results
18th Jul 20227:00 amRNSNotice of Results
31st May 202211:40 amRNSTotal Voting Rights
26th May 20228:56 amRNSHolding(s) in Company
17th May 20221:57 pmRNSDirector/PDMR Shareholding and Total Voting Rights
5th May 20222:10 pmRNSDirector Shareholding
29th Apr 202210:56 amRNSTotal Voting Rights
28th Apr 202212:24 pmRNSResult of AGM and Directorate Change
28th Apr 20227:00 amRNSAGM Statement
12th Apr 202211:50 amRNSBlock Listing Application
11th Apr 20222:30 pmRNSBlock listing Interim Review
4th Apr 20227:00 amRNSGrant of awards under 2020 Deferred Bonus Plan
22nd Mar 20227:00 amRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSAudited Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.